PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data ...
SEATTLE--(BUSINESS WIRE)--ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the ...
In vivo antitumor efficacy with significant tumor growth inhibition in multiple models with varying levels of FOLR1 expression Highly promising safety results in non-human primates, enabling a broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results